Energetics in hypertrophic cardiomyopathy: Translation between MRI, PET and cardiac myofilament function (ENGINE study)

Netherlands Heart Journal

Volumn 21, Issue 12, 2013, Pages 567-571

  Guclu A ^a,e   Germans, T ^a   Witjas Paalberends, E R ^a   Stienen, G J M ^a   Brouwer, W P ^a   Harms, H J ^a   Marcus, J T ^a   Vonk, A B A ^a   Stooker, W ^b   Yilmaz, A ^c   Klein, P ^c   ten Berg, J M ^c   Kluin, J ^d   Asselbergs, F W ^d   Lammertsma, A A ^a   Knaapen, P ^a   van Rossum, A C ^a   van der Velden, J ^a,e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Carrier; Hypertrophic cardiomyopathy; Myocardial energetics; Sarcomeremutations

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CARDIAC MYOSIN; CREATINE PHOSPHATE; GADOLINIUM;

AORTA VALVE STENOSIS; ARTICLE; BIOPSY; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR MAGNETIC RESONANCE; DISEASE ASSOCIATION; DISEASE COURSE; ENERGY TRANSFER; FOLLOW UP; HEART CONTRACTION; HEART EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HYPERTROPHIC CARDIOMYOPATHY; MUTATION; POSITRON EMISSION TOMOGRAPHY; SARCOMERE;

EID: 84891505117     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-013-0478-8     Document Type: Article

References (21)

1. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308-1320.
2. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet. 2000;355:58-60.
3. Hoskins AC, Jacques A, Bardswell SC, et al. Normal passive visco elasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2010;49:737-745.
4. Kraft T, Witjas-Paalberends ER, Boontje NM, et al. Familial hyper trophic cardiomyopathy: functional effects of myosin mutation R723G in cardiomyocytes. J Mol Cell Cardiol. 2013;57:13-22.
5. van Dijk SJ, Dooijes D, dos Remedios CG, et al. Cardiac myosin binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 2009;119:1473-1483.
6. van Dijk SJ, Paalberends ER, Najafi A, et al. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function. Circ Heart Fail. 2012;5:36-46.
7. Witjas-Paalberends ER, Piroddi N, Stam K, et al. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovasc Res. 2013;99: 432-441.
8. Belus A, Piroddi N, Scellini B, et al. The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates ten sion generation and relaxation of human cardiac myofibrils. J Physiol. 2008;586:3639-3644.
9. Elliott K, Watkins H, Redwood CS. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomy opathy. J Biol Chem. 2000;275:22069-22074.
10. Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002; 105:2992-2997.
11. Sequeira V, Wijnker PJ, Nijenkamp LL, et al. Perturbed lengthdependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res. 2013;112:1491-1505.
12. Ashrafian H, Redwood C, Blair E. Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. Trends Genet. 2003;19: 263-8.
13. Spindler M, Saupe KW, Christe ME, et al. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest. 1998;101:1775-1783.
14. Javadpour MM, Tardiff JC, Pinz I, et al. Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J Clin Invest. 2003;112:768-75.
15. Montgomery DE, Tardiff JC, Chandra M. Cardiac troponin T mutations: correlation between the type of mutation and the nature of myofilament dysfunction in transgenic mice. J Physiol. 2001;536: 583-592.
16. Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776-1782.
17. Timmer SA, Germans T, Brouwer WP, et al. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are character ized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail. 2011;13: 1283-1289.
18. Abozguia K, Elliott P, McKenna W, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capac ity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122:1562-1569.
19. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int J Cardiovasc Imaging. 2002;18: 539-542.
20. Knaapen P, Germans T, Knuuti J, et al. Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation. 2007;115:918-927.
21. Narolska NA, van Loon RB, Boontje NM, et al. Myocardial contraction is 5-fold more economical in ventricular than in atrial human tissue. Cardiovasc Res. 2005;65:221-229.